Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer.
Hwang JH, Yoo HJ, Lim MC, Seo SS, Park SY, Kang S.
Anticancer Drugs. 2011 Dec 7. [Epub ahead of print]
Related citations
Long-term remission in a patient with heavily pretreated, advanced ovarian cancer achieved by bevacizumab and metronomic cyclophosphamide treatment.
Aigner J, Bischofs E, Hallscheidt P, Sohn C, Schneeweiss A, Eichbaum M.
Anticancer Drugs. 2011 Nov;22(10):1030-3.
Glycogen synthase kinase 3β inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth.
Hilliard TS, Gaisina IN, Muehlbauer AG, Gaisin AM, Gallier F, Burdette JE.
Anticancer Drugs. 2011 Nov;22(10):978-85.
Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful?
Syrigou E, Makrilia N, Vassias A, Nikolaidis I, Xyla V, Manolopoulos L, Syrigos K.
Anticancer Drugs. 2010 Mar;21(3):333-8.
NF-kappaB is involved in SHetA2 circumvention of TNF-alpha resistance, but not induction of intrinsic apoptosis.
Chengedza S, Benbrook DM.
Anticancer Drugs. 2010 Mar;21(3):297-305.
Apparent beneficial effects by nab-paclitaxel in the treatment of refractory metastatic ovarian carcinoma.
Agheli A, Park SC, Huang CJ, Wang JC.
Anticancer Drugs. 2009 Jul;20(6):525-6. No abstract available.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on